RxDoctor Payments DataLook up a doctor →

Larry Blankenship, MD

Neurology · Anderson, INNPI 1407947807

Payments from drug & device makers

$68,792in general payments, 2019–2025

Across 915 payments — averaging $75.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$34K
  • UCB SA$13K
  • Biohaven Pharmaceuticals, Inc.$9K
  • AbbVie$3K
  • Sanofi$983
  • Acadia Pharmaceuticals Inc$946
  • plus $9K from 54 others

What the payments were for

  • Travel & lodging$1,0266%
  • Food & beverage$15,26991%
  • Education$5613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis120$33,524
UCB SA11$12,697
Biohaven Pharmaceuticals, Inc.21$8,568
AbbVie(2 entities)198$2,544
Sanofi34$983
Acadia Pharmaceuticals Inc62$946
Biogen32$769
MDD US Operations, LLC14$757
Amgen(2 entities)40$600
Eisai Inc.28$586
Lilly USA, LLC43$517
UCB, Inc.21$448
Harmony Biosciences LLC8$377
Vanda Pharmaceuticals Inc.4$357
CSL Behring14$297
AstraZeneca(2 entities)14$287
Neurocrine Biosciences, Inc.14$284
Biohaven Pharmaceutical Holding Company Ltd.21$270
EMD Serono, Inc.15$241
TG Therapeutics, Inc.13$237
Jazz Pharmaceuticals Inc.9$237
Argenx US, Inc.12$232
Tanabe Pharma America, Inc.10$231
Pfizer15$221
Amneal Pharmaceuticals LLC11$199
Sunovion Pharmaceuticals Inc.14$191
Teva Pharmaceuticals USA, Inc.13$189
Genentech USA, Inc.11$182
Catalyst Pharmaceuticals, Inc.4$137
Lundbeck LLC8$137
Avadel CNS Pharmaceuticals, LLC6$118
Livanova USA, Inc.3$114
Avanos Medical2$91
SK Life Science, Inc.5$76
Neurelis, Inc.3$74
Amylyx Pharmaceuticals, Inc.3$69
Adamas Pharmaceuticals, Inc.5$68
Banner Life Sciences, LLC3$65
Mallinckrodt Hospital Products Inc.3$61
Abbott2$51
Otsuka America Pharmaceutical, Inc.3$51
Grifols USA, LLC3$50
Supernus Pharmaceuticals, Inc.4$47
Axsome Therapeutics, Inc.2$42
Johnson & Johnson3$41
Ipsen Biopharmaceuticals, Inc2$36
Fisher & Paykel Healthcare Inc2$34
Greenwich Biosciences, Inc.2$34
Globus Medical1$34
Sumitomo Pharma America, Inc.3$32
Scilex Pharmaceuticals Inc.2$32
Inspire Medical Systems, Inc.1$30
Takeda Pharmaceuticals U.S.A., Inc.2$29
Avanir Pharmaceuticals, Inc.2$29
OWP Pharmaceuticals, Inc.2$28
Bausch Health US, LLC1$24
Averitas Pharma Inc.1$20
Itamar Medical Inc1$20
Merz Pharmaceuticals, LLC1$20
Sanofi-aventis U.S. LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,792 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,160,451
Medicare patients
660
Services billed
21,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam19$498,926
IngrezzaValbenazine Tosylate21$171,954
Avonex Pen (4 Pack)Interferon Beta-1a13$107,514
Avonex (4 Pack)Interferon Beta-1a12$101,674
Glatiramer Acetate12$32,256
Aimovig AutoinjectorErenumab-Aooe34$31,651
Nurtec OdtRimegepant Sulfate22$25,229
RytaryCarbidopa/Levodopa16$24,116
NuedextaDextromethorphan Hbr/Quinidine13$23,076
EpidiolexCannabidiol (Cbd)14$22,981
QuliptaAtogepant20$22,146
HorizantGabapentin Enacarbil13$15,622
Emgality PenGalcanezumab-Gnlm19$13,200
Carbidopa-LevodopaCarbidopa/Levodopa410$11,605
NeuproRotigotine12$10,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$182$498,92619 claims
Neurocrine Biosciences, Inc.Ingrezza$284$171,95421 claims
BiogenAvonex (4 Pack)$769$101,67412 claims
AbbVieQulipta, Savella$2,544$27,90032 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$199$25,85441 claims
PfizerNurtec Odt$221$25,22922 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29$23,07613 claims
UCB, Inc.Neupro$448$10,46412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →